Literature DB >> 21835320

Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.

Iacopo Olivotto1, Francesca Girolami, Roberto Sciagrà, Michael J Ackerman, Barbara Sotgia, J Martijn Bos, Stefano Nistri, Aurelio Sgalambro, Camilla Grifoni, Francesca Torricelli, Paolo G Camici, Franco Cecchi.   

Abstract

OBJECTIVES: The purpose of this study was to assess myocardial blood flow (MBF) using positron emission tomography in patients with hypertrophic cardiomyopathy (HCM) according to genetic status.
BACKGROUND: Coronary microvascular dysfunction is an important feature of HCM, associated with ventricular remodeling and heart failure. We recently demonstrated the increased prevalence of systolic dysfunction in patients with HCM with sarcomere myofilament gene mutations and postulated an association between genetic status and coronary microvascular dysfunction.
METHODS: Maximum MBF (intravenous dipyridamole, 0.56 mg/kg; Dip-MBF) was measured using (13)N-labeled ammonia in 61 patients with HCM (age 38 ± 14 years), genotyped by automatic DNA sequencing of 8 myofilament-encoding genes (myosin-binding protein C, beta-myosin heavy chain, regulatory and essential light chains, troponin T, troponin I, troponin C, alpha-tropomyosin, and alpha-actin). In 35 patients, cardiac magnetic resonance imaging was performed.
RESULTS: Fifty-three mutations were identified in 42 of the 61 patients (genotype positive; 69%). Despite similar clinical profiles, genotype-positive patients with HCM showed substantially lower Dip-MBF compared with that of genotype-negative patients (1.7 ± 0.6 ml/min/g vs. 2.4 ± 1.2 ml/min/g; p < 0.02). A Dip-MBF <1.5 ml/min/g had 81% positive predictive value for genotype-positive status and implied a 3.5-fold independent increase in likelihood of carrying myofilament gene mutations (hazard ratio: 3.52; 95% confidence interval: 1.05 to 11.7; p = 0.04). At cardiac magnetic resonance imaging, the prevalence of late gadolinium enhancement was greater in genotype-positive patients (22 of 23 [96%] compared with 8 of 12 [67%] genotype-negative patients; p = 0.038).
CONCLUSIONS: Patients with HCM with sarcomere myofilament mutations are characterized by more severe impairment of microvascular function and increased prevalence of myocardial fibrosis, compared with genotype-negative individuals. These findings suggest a direct link between sarcomere gene mutations and adverse remodeling of the microcirculation in HCM, accounting for the increased long-term prevalence of ventricular dysfunction and heart failure in genotype-positive patients.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835320     DOI: 10.1016/j.jacc.2011.05.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  47 in total

1.  The role of coronary microvascular disorder in congestive heart failure.

Authors:  Georges E Haddad; Sana Chams; Nour Chams
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 2.  Linking myofilaments to sudden cardiac death: recent advances.

Authors:  Sabine Huke
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

3.  Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.

Authors:  Helga Castagnoli; Cecilia Ferrantini; Raffaele Coppini; Alessandro Passeri; Katia Baldini; Valentina Berti; Franco Cecchi; Iacopo Olivotto; Roberto Sciagrà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-16       Impact factor: 9.236

4.  Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.

Authors:  Daisuke Tezuka; Hisanori Kosuge; Masahiro Terashima; Nozomu Koyama; Tadashi Kishida; Yuko Tada; Jun-Ichi Suzuki; Tetsuo Sasano; Takashi Ashikaga; Kenzo Hirao; Mitsuaki Isobe
Journal:  Heart Vessels       Date:  2017-11-22       Impact factor: 2.037

Review 5.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

6.  Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

Authors:  G Neal Kay
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 7.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

8.  Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix.

Authors:  Matthew K Stephenson; Sean Lenihan; Roman Covarrubias; Ryan M Huttinger; Richard J Gumina; Douglas B Sawyer; Cristi L Galindo
Journal:  J Vis Exp       Date:  2016-06-14       Impact factor: 1.355

Review 9.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

Review 10.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.